Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.37 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15682776 | 0.81 | RIPK1 (0.53) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL127089 | 0.79 | POLB (0.46) | MEN1KMT2AMAPK14ROCK2ROCK1 | |
| SCHEMBL3557822 | 0.77 | CYP1A2 (0.48) | MEN1KMT2AMAPK14ROCK2ROCK1 | |
| SCHEMBL14232838 | 0.76 | NPSR1 (0.53) | MEN1KMT2AMAPK14ROCK2ROCK1 | |
| SCHEMBL15682780 | 0.75 | SRC (0.52) | MEN1KMT2AALDH1A1 | |
| SCHEMBL17235930 | 0.75 | KMT2A (0.51) | MEN1KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL23052072 | 0.73 | CYP1A2 (0.50) | MEN1KMT2AMAPK14ALDH1A1P2RX7 | |
| SCHEMBL4034946 | 0.73 | ALDH1A1 (0.51) | MEN1KMT2AMAPK14ALDH1A1MAPT | |
| SCHEMBL28948874 | 0.73 | KMT2A (0.44) | MEN1KMT2AMAPK14ROCK2ROCK1 | |
| SCHEMBL15682670 | 0.73 | LMNA (0.56) | KMT2AALDH1A1L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387356-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INHIBITOR AND METHOD OF USE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-12-08 | — | — | US | disclosed |
| US-20200147007-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INHIBITOR AND METHOD OF USE | EASTERN MICHIGAN UNIVERSITY | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387356-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INHIBITOR AND METHOD OF USE | SERPINE1, PLAT, SERPINC1 | MEN1 1743/4885KMT2A 3934/4885MAPK14 2560/4885 |
| US-20200147007-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INHIBITOR AND METHOD OF USE | SERPINE1, PLAT, SERPINC1 | MEN1 1743/4885KMT2A 3934/4885MAPK14 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.